Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C39H45N2O6.I |
| Molecular Weight | 764.6889 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[I-].COC1=CC=C2C[C@@H]3C4=C(CC[N+]3(C)C)C=C(OC)C(OC)=C4OC5=CC=C(C[C@@H]6N(C)CCC7=CC(OC)=C(OC1=C2)C=C67)C=C5
InChI
InChIKey=ZRILZUBJODJELN-LBYXUWKHSA-M
InChI=1S/C39H45N2O6.HI/c1-40-16-14-26-21-33(43-5)35-23-29(26)30(40)18-24-8-11-28(12-9-24)46-39-37-27(22-36(44-6)38(39)45-7)15-17-41(2,3)31(37)19-25-10-13-32(42-4)34(20-25)47-35;/h8-13,20-23,30-31H,14-19H2,1-7H3;1H/q+1;/p-1/t30-,31+;/m0./s1
Dimethyltubocurarine (metocurine) is a non-depolarizing muscle relaxant. It binds to muscle acetylcholine receptor by bridging the to alpha and non-alpha subunits from the ligand binding site. Dimethyltubocurarine was used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.
Approval Year
Sample Use Guides
Dimethyl-tubocurarine iodide is administered intravenously in isotonic sodium chloride solution for muscle relaxtion in surgery. The average initial dose is approximately 2 mg (80 units) and is injected slowly over a period of one to one
and one-half minutes.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
0Q5R726FHX
Created by
admin on Mon Mar 31 22:03:48 GMT 2025 , Edited by admin on Mon Mar 31 22:03:48 GMT 2025
|
PRIMARY | |||
|
36653-49-3
Created by
admin on Mon Mar 31 22:03:48 GMT 2025 , Edited by admin on Mon Mar 31 22:03:48 GMT 2025
|
PRIMARY | |||
|
76957755
Created by
admin on Mon Mar 31 22:03:48 GMT 2025 , Edited by admin on Mon Mar 31 22:03:48 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
